Treatment with anti-interleukin 23 antibody ameliorates disease in lupus-prone mice

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Kyttaris, Vasileios C ^a,b   Kampagianni, Ourania ^a   Tsokos, George C ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 17; INTERLEUKIN 23 ANTIBODY; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 23P19; INTERLEUKIN 23P19 ANTIBODY; UNCLASSIFIED DRUG; ANTI IGG; ANTI-IGG; ANTIIDIOTYPIC ANTIBODY; INTERLEUKIN 23;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DISEASE COURSE; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT OUTCOME; ANIMAL; DRUG ANTAGONISM; HUMAN; IMMUNOLOGY; LUPUS ERYTHEMATOSUS NEPHRITIS; PATHOLOGY; ANTAGONISTS AND INHIBITORS; COMPLICATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS;

MURINAE; MUS; RATTUS;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; HUMANS; INTERLEUKIN-23; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MICE; T-LYMPHOCYTES;

EID: 84879407426     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/861028     Document Type: Article

References (9)

1. Peters A., Lee Y., Kuchroo V. K., The many faces of Th17 cells. Current Opinion in Immunology 2011 23 6 702 706 2-s2.0-82955232358 10.1016/j.coi.2011. 08.007
2. Awasthi A., Riol-Blanco L., Jäger A., Korn T., Pot C., Galileos G., Bettelli E., Kuchroo V. K., Oukka M., Cutting edge: IL-23 receptor GFP reporter mice reveal distinct populations of IL-17-producing cells. Journal of Immunology 2009 182 10 5904 5908 2-s2.0-68649090645 10.4049/jimmunol.0900732
3. Tsokos G. C., Mechanisms of disease: systemic lupus erythematosus. The New England Journal of Medicine 2011 365 22 2110 2121 2-s2.0-82555196095
4. Zhang Z., Kyttaris V. C., Tsokos G. C., The role of IL-23/IL-17 axis in lupus nephritis. Journal of Immunology 2009 183 5 3160 3169 2-s2.0-70349238893 10.4049/jimmunol.0900385
5. Kyttaris V. C., Zhang Z., Kuchroo V. K., Oukka M., Tsokos G. C., Cutting edge: IL-23 receptor deficiency prevents the development of lupus nephritis in C57BL/6-lpr/lpr mice. Journal of Immunology 2010 184 9 4605 4609 2-s2.0-77953196382 10.4049/jimmunol.0903595
6. Kyttaris V. C., Zhang Z., Kampagianni O., Tsokos G. C., Calcium signaling in systemic lupus erythematosus T cells: a treatment target. Arthritis and Rheumatism 2011 63 7 2058 2066 2-s2.0-79959852739 10.1002/art.30353
7. Krintel S. B., Grunert V. P., Hetland M. L., Johansen J. S., Rothfuss M., Palermo G., Essioux L., Klause U., The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure. Rheumatology 2013 10.1093/rheumatology/ket017
8. Pisitkun P., Ha H. L., Wang H., Claudio E., Tivy C. C., Zhou H., Mayadas T. N., Illei G. G., Siebenlist U., Interleukin-17 cytokines are critical in development of fatal lupus glomerulonephritis. Immunity 2012 37 6 1104 1115 10.1016/j.immuni.2012.08.014
9. Griffiths C. E. M., Strober B. E., van de Kerkhof P., Ho V., Fidelus-Gort R., Yeilding N., Guzzo C., Xia Y., Zhou B., Li S., Dooley L. T., Goldstein N. H., Menter A., Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. The New England Journal of Medicine 2010 362 2 118 128 2-s2.0-74249094930 10.1056/NEJMoa0810652